Размер шрифта
Цветовая схема
Изображения
Форма
Межсимвольный интервал
Межстрочный интервал
стандартные настройки
обычная версия сайта
закрыть
  • Вход
  • Регистрация
  • Помощь
Выбрать БД
Простой поискРасширенный поискИстория поисков
Главная / Результаты поиска

IL-23/IL-17 inhibitors in immunoinflammatory rheumatic diseases: New Horizons

Насонов Е. Л., Коротаева Т. В., Дубинина Т. В., Лила А. М.
Научно-практическая ревматология
Т. 57, Вып. 4, С. 400-406
Опубликовано: 2019
Тип ресурса: Статья

DOI:10.14412/1995-4484-2019-400-406

Аннотация:
Recently, more attention has been given to Th17 cells, the pathological activation of which plays a leading role in the development of a wide spectrum of human immunoinflammatory diseases (IID), including rheumatoid arthritis, psoriasis, ankylosing spondylitis, psoriatic arthritis, inflammatory bowel diseases, etc. This has served as an incentive to design new biological agents and small molecules, the main mechanism of action of which is based on blocking the pathological effects of interleukin-17 (IL-17), others are associated with the activation of Th17 cells cytokines or signaling pathways that regulate the effects of these cytokines. The review discusses current ideas about the mechanisms regulating the formation and functional activity of IL-17 family cytokines, as well as evidence for the importance of these cytokines in the pathogenesis of IID. © 2019 Ima-Press Publishing House. All rights reserved.
Ключевые слова:
Ankylosing spondylitis; Biological agents; IL-23/IL-17 axis; Psoriasis; Psoriatic arthritis; Rheumatoid arthritis
interleukin 17; interleukin 17 inhibitor; interleukin 23; interleukin 23 inhibitor; protein inhibitor; unclassified drug; Article; drug mechanism; evidence based practice; rheumatic disease; signal transduction; Th17 cell
Язык текста: Русский
ISSN: 1995-4492
Насонов Е. Л. Евгений Львович 1948-
Коротаева Т. В.
Дубинина Т. В.
Лила А. М.
Nasonov E. L. Evgenij L`vovich 1948-
Korotaeva T. V.
Dubinina T. V.
Lila A. M.
IL-23/IL-17 inhibitors in immunoinflammatory rheumatic diseases: New Horizons
Текст визуальный непосредственный
Научно-практическая ревматология
ИМА-Пресс
Т. 57, Вып. 4 С. 400-406
2019
Статья
Ankylosing spondylitis Biological agents IL-23/IL-17 axis Psoriasis Psoriatic arthritis Rheumatoid arthritis
interleukin 17 interleukin 17 inhibitor interleukin 23 interleukin 23 inhibitor protein inhibitor unclassified drug Article drug mechanism evidence based practice rheumatic disease signal transduction Th17 cell
Recently, more attention has been given to Th17 cells, the pathological activation of which plays a leading role in the development of a wide spectrum of human immunoinflammatory diseases (IID), including rheumatoid arthritis, psoriasis, ankylosing spondylitis, psoriatic arthritis, inflammatory bowel diseases, etc. This has served as an incentive to design new biological agents and small molecules, the main mechanism of action of which is based on blocking the pathological effects of interleukin-17 (IL-17), others are associated with the activation of Th17 cells cytokines or signaling pathways that regulate the effects of these cytokines. The review discusses current ideas about the mechanisms regulating the formation and functional activity of IL-17 family cytokines, as well as evidence for the importance of these cytokines in the pathogenesis of IID. © 2019 Ima-Press Publishing House. All rights reserved.